What is the projected market valuation of the Hepatic Encephalopathy Treatment Market by 2035?

The Hepatic Encephalopathy Treatment Market is projected to reach approximately 3.195 USD Billion by 2035. Read More

What was the market valuation of the Hepatic Encephalopathy Treatment Market in 2024?

In 2024, the market valuation of the Hepatic Encephalopathy Treatment Market was 1.567 USD Billion. Read More

What is the expected CAGR for the Hepatic Encephalopathy Treatment Market during the forecast period 2025 - 2035?

The expected CAGR for the Hepatic Encephalopathy Treatment Market during the forecast period 2025 - 2035 is 6.69%. Read More

Which companies are considered key players in the Hepatic Encephalopathy Treatment Market?

Key players in the Hepatic Encephalopathy Treatment Market include AbbVie, Bristol-Myers Squibb, Horizon Therapeutics, Mylan, Salix Pharmaceuticals, Sandoz, Takeda Pharmaceutical, and Valeant Pharmaceuticals. Read More

What are the main treatment types in the Hepatic Encephalopathy Treatment Market?

The main treatment types in the Hepatic Encephalopathy Treatment Market include Drug Therapy, Liver Transplantation, and Other Treatment Options. Read More

How much revenue is generated from Drug Therapy in the Hepatic Encephalopathy Treatment Market?

Revenue from Drug Therapy in the Hepatic Encephalopathy Treatment Market is expected to range from 0.85 to 1.5 USD Billion. Read More

What is the revenue range for Lactulose in the Hepatic Encephalopathy Treatment Market?

The revenue range for Lactulose in the Hepatic Encephalopathy Treatment Market is projected to be between 0.75 and 0.9 USD Billion. Read More

What is the market performance for Mild Hepatic Encephalopathy in terms of revenue?

The market performance for Mild Hepatic Encephalopathy is expected to generate revenue between 0.627 and 1.305 USD Billion. Read More

What is the expected revenue for Adult patients in the Hepatic Encephalopathy Treatment Market?

The expected revenue for Adult patients in the Hepatic Encephalopathy Treatment Market is projected to be between 1.41 and 2.875 USD Billion. Read More

What are the primary etiologies contributing to the Hepatic Encephalopathy Treatment Market?

Primary etiologies contributing to the Hepatic Encephalopathy Treatment Market include Cirrhosis, Hepatitis, Alcohol use disorder, and other factors. Read More

Hepatic Encephalopathy Treatment Market

ID: MRFR/HC/35965-HCR

100 Pages

Nidhi Mandole

Last Updated: April 06, 2026

Hepatic Encephalopathy Treatment Market Research Report: Size, Share, Trend Analysis By Treatment Type (Drug Therapy, Liver Transplantation, Other Treatment Options), By Drug Class (Lactulose, Rifaximin, Antibiotics, Others), By Disease Severity (Mild Hepatic Encephalopathy, Moderate Hepatic Encephalopathy, Severe Hepatic Encephalopathy), By Patient Age Group (Pediatric, Adult), By Etiology (Cirrhosis, Hepatitis, Alcohol use disorder, Other) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Type (USD Billion)
  1. 4.1.1 Drug Therapy
  2. 4.1.2 Liver Transplantation
  3. 4.1.3 Other Treatment Options
2. 4.2 Healthcare, BY Drug Class (USD Billion)
  1. 4.2.1 Lactulose
  2. 4.2.2 Rifaximin
  3. 4.2.3 Antibiotics
  4. 4.2.4 Others
3. 4.3 Healthcare, BY Disease Severity (USD Billion)
  1. 4.3.1 Mild Hepatic Encephalopathy
  2. 4.3.2 Moderate Hepatic Encephalopathy
  3. 4.3.3 Severe Hepatic Encephalopathy
4. 4.4 Healthcare, BY Patient Age Group (USD Billion)
  1. 4.4.1 Pediatric
  2. 4.4.2 Adult
5. 4.5 Healthcare, BY Etiology (USD Billion)
  1. 4.5.1 Cirrhosis
  2. 4.5.2 Hepatitis
  3. 4.5.3 Alcohol use disorder
  4. 4.5.4 Other
6. 4.6 Healthcare, BY Region (USD Billion)
  1. 4.6.1 North America
    1. 4.6.1.1 US
    2. 4.6.1.2 Canada
  2. 4.6.2 Europe
    1. 4.6.2.1 Germany
    2. 4.6.2.2 UK
    3. 4.6.2.3 France
    4. 4.6.2.4 Russia
    5. 4.6.2.5 Italy
    6. 4.6.2.6 Spain
    7. 4.6.2.7 Rest of Europe
  3. 4.6.3 APAC
    1. 4.6.3.1 China
    2. 4.6.3.2 India
    3. 4.6.3.3 Japan
    4. 4.6.3.4 South Korea
    5. 4.6.3.5 Malaysia
    6. 4.6.3.6 Thailand
    7. 4.6.3.7 Indonesia
    8. 4.6.3.8 Rest of APAC
  4. 4.6.4 South America
    1. 4.6.4.1 Brazil
    2. 4.6.4.2 Mexico
    3. 4.6.4.3 Argentina
    4. 4.6.4.4 Rest of South America
  5. 4.6.5 MEA
    1. 4.6.5.1 GCC Countries
    2. 4.6.5.2 South Africa
    3. 4.6.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 AbbVie (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bristol-Myers Squibb (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Horizon Therapeutics (IE)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Mylan (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Salix Pharmaceuticals (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Sandoz (CH)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Takeda Pharmaceutical (JP)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Valeant Pharmaceuticals (CA)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY TYPE
4. 6.4 US MARKET ANALYSIS BY DRUG CLASS
5. 6.5 US MARKET ANALYSIS BY DISEASE SEVERITY
6. 6.6 US MARKET ANALYSIS BY PATIENT AGE GROUP
7. 6.7 US MARKET ANALYSIS BY ETIOLOGY
8. 6.8 CANADA MARKET ANALYSIS BY TYPE
9. 6.9 CANADA MARKET ANALYSIS BY DRUG CLASS
10. 6.10 CANADA MARKET ANALYSIS BY DISEASE SEVERITY
11. 6.11 CANADA MARKET ANALYSIS BY PATIENT AGE GROUP
12. 6.12 CANADA MARKET ANALYSIS BY ETIOLOGY
13. 6.13 EUROPE MARKET ANALYSIS
14. 6.14 GERMANY MARKET ANALYSIS BY TYPE
15. 6.15 GERMANY MARKET ANALYSIS BY DRUG CLASS
16. 6.16 GERMANY MARKET ANALYSIS BY DISEASE SEVERITY
17. 6.17 GERMANY MARKET ANALYSIS BY PATIENT AGE GROUP
18. 6.18 GERMANY MARKET ANALYSIS BY ETIOLOGY
19. 6.19 UK MARKET ANALYSIS BY TYPE
20. 6.20 UK MARKET ANALYSIS BY DRUG CLASS
21. 6.21 UK MARKET ANALYSIS BY DISEASE SEVERITY
22. 6.22 UK MARKET ANALYSIS BY PATIENT AGE GROUP
23. 6.23 UK MARKET ANALYSIS BY ETIOLOGY
24. 6.24 FRANCE MARKET ANALYSIS BY TYPE
25. 6.25 FRANCE MARKET ANALYSIS BY DRUG CLASS
26. 6.26 FRANCE MARKET ANALYSIS BY DISEASE SEVERITY
27. 6.27 FRANCE MARKET ANALYSIS BY PATIENT AGE GROUP
28. 6.28 FRANCE MARKET ANALYSIS BY ETIOLOGY
29. 6.29 RUSSIA MARKET ANALYSIS BY TYPE
30. 6.30 RUSSIA MARKET ANALYSIS BY DRUG CLASS
31. 6.31 RUSSIA MARKET ANALYSIS BY DISEASE SEVERITY
32. 6.32 RUSSIA MARKET ANALYSIS BY PATIENT AGE GROUP
33. 6.33 RUSSIA MARKET ANALYSIS BY ETIOLOGY
34. 6.34 ITALY MARKET ANALYSIS BY TYPE
35. 6.35 ITALY MARKET ANALYSIS BY DRUG CLASS
36. 6.36 ITALY MARKET ANALYSIS BY DISEASE SEVERITY
37. 6.37 ITALY MARKET ANALYSIS BY PATIENT AGE GROUP
38. 6.38 ITALY MARKET ANALYSIS BY ETIOLOGY
39. 6.39 SPAIN MARKET ANALYSIS BY TYPE
40. 6.40 SPAIN MARKET ANALYSIS BY DRUG CLASS
41. 6.41 SPAIN MARKET ANALYSIS BY DISEASE SEVERITY
42. 6.42 SPAIN MARKET ANALYSIS BY PATIENT AGE GROUP
43. 6.43 SPAIN MARKET ANALYSIS BY ETIOLOGY
44. 6.44 REST OF EUROPE MARKET ANALYSIS BY TYPE
45. 6.45 REST OF EUROPE MARKET ANALYSIS BY DRUG CLASS
46. 6.46 REST OF EUROPE MARKET ANALYSIS BY DISEASE SEVERITY
47. 6.47 REST OF EUROPE MARKET ANALYSIS BY PATIENT AGE GROUP
48. 6.48 REST OF EUROPE MARKET ANALYSIS BY ETIOLOGY
49. 6.49 APAC MARKET ANALYSIS
50. 6.50 CHINA MARKET ANALYSIS BY TYPE
51. 6.51 CHINA MARKET ANALYSIS BY DRUG CLASS
52. 6.52 CHINA MARKET ANALYSIS BY DISEASE SEVERITY
53. 6.53 CHINA MARKET ANALYSIS BY PATIENT AGE GROUP
54. 6.54 CHINA MARKET ANALYSIS BY ETIOLOGY
55. 6.55 INDIA MARKET ANALYSIS BY TYPE
56. 6.56 INDIA MARKET ANALYSIS BY DRUG CLASS
57. 6.57 INDIA MARKET ANALYSIS BY DISEASE SEVERITY
58. 6.58 INDIA MARKET ANALYSIS BY PATIENT AGE GROUP
59. 6.59 INDIA MARKET ANALYSIS BY ETIOLOGY
60. 6.60 JAPAN MARKET ANALYSIS BY TYPE
61. 6.61 JAPAN MARKET ANALYSIS BY DRUG CLASS
62. 6.62 JAPAN MARKET ANALYSIS BY DISEASE SEVERITY
63. 6.63 JAPAN MARKET ANALYSIS BY PATIENT AGE GROUP
64. 6.64 JAPAN MARKET ANALYSIS BY ETIOLOGY
65. 6.65 SOUTH KOREA MARKET ANALYSIS BY TYPE
66. 6.66 SOUTH KOREA MARKET ANALYSIS BY DRUG CLASS
67. 6.67 SOUTH KOREA MARKET ANALYSIS BY DISEASE SEVERITY
68. 6.68 SOUTH KOREA MARKET ANALYSIS BY PATIENT AGE GROUP
69. 6.69 SOUTH KOREA MARKET ANALYSIS BY ETIOLOGY
70. 6.70 MALAYSIA MARKET ANALYSIS BY TYPE
71. 6.71 MALAYSIA MARKET ANALYSIS BY DRUG CLASS
72. 6.72 MALAYSIA MARKET ANALYSIS BY DISEASE SEVERITY
73. 6.73 MALAYSIA MARKET ANALYSIS BY PATIENT AGE GROUP
74. 6.74 MALAYSIA MARKET ANALYSIS BY ETIOLOGY
75. 6.75 THAILAND MARKET ANALYSIS BY TYPE
76. 6.76 THAILAND MARKET ANALYSIS BY DRUG CLASS
77. 6.77 THAILAND MARKET ANALYSIS BY DISEASE SEVERITY
78. 6.78 THAILAND MARKET ANALYSIS BY PATIENT AGE GROUP
79. 6.79 THAILAND MARKET ANALYSIS BY ETIOLOGY
80. 6.80 INDONESIA MARKET ANALYSIS BY TYPE
81. 6.81 INDONESIA MARKET ANALYSIS BY DRUG CLASS
82. 6.82 INDONESIA MARKET ANALYSIS BY DISEASE SEVERITY
83. 6.83 INDONESIA MARKET ANALYSIS BY PATIENT AGE GROUP
84. 6.84 INDONESIA MARKET ANALYSIS BY ETIOLOGY
85. 6.85 REST OF APAC MARKET ANALYSIS BY TYPE
86. 6.86 REST OF APAC MARKET ANALYSIS BY DRUG CLASS
87. 6.87 REST OF APAC MARKET ANALYSIS BY DISEASE SEVERITY
88. 6.88 REST OF APAC MARKET ANALYSIS BY PATIENT AGE GROUP
89. 6.89 REST OF APAC MARKET ANALYSIS BY ETIOLOGY
90. 6.90 SOUTH AMERICA MARKET ANALYSIS
91. 6.91 BRAZIL MARKET ANALYSIS BY TYPE
92. 6.92 BRAZIL MARKET ANALYSIS BY DRUG CLASS
93. 6.93 BRAZIL MARKET ANALYSIS BY DISEASE SEVERITY
94. 6.94 BRAZIL MARKET ANALYSIS BY PATIENT AGE GROUP
95. 6.95 BRAZIL MARKET ANALYSIS BY ETIOLOGY
96. 6.96 MEXICO MARKET ANALYSIS BY TYPE
97. 6.97 MEXICO MARKET ANALYSIS BY DRUG CLASS
98. 6.98 MEXICO MARKET ANALYSIS BY DISEASE SEVERITY
99. 6.99 MEXICO MARKET ANALYSIS BY PATIENT AGE GROUP
100. 6.100 MEXICO MARKET ANALYSIS BY ETIOLOGY
101. 6.101 ARGENTINA MARKET ANALYSIS BY TYPE
102. 6.102 ARGENTINA MARKET ANALYSIS BY DRUG CLASS
103. 6.103 ARGENTINA MARKET ANALYSIS BY DISEASE SEVERITY
104. 6.104 ARGENTINA MARKET ANALYSIS BY PATIENT AGE GROUP
105. 6.105 ARGENTINA MARKET ANALYSIS BY ETIOLOGY
106. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
107. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG CLASS
108. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISEASE SEVERITY
109. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT AGE GROUP
110. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY ETIOLOGY
111. 6.111 MEA MARKET ANALYSIS
112. 6.112 GCC COUNTRIES MARKET ANALYSIS BY TYPE
113. 6.113 GCC COUNTRIES MARKET ANALYSIS BY DRUG CLASS
114. 6.114 GCC COUNTRIES MARKET ANALYSIS BY DISEASE SEVERITY
115. 6.115 GCC COUNTRIES MARKET ANALYSIS BY PATIENT AGE GROUP
116. 6.116 GCC COUNTRIES MARKET ANALYSIS BY ETIOLOGY
117. 6.117 SOUTH AFRICA MARKET ANALYSIS BY TYPE
118. 6.118 SOUTH AFRICA MARKET ANALYSIS BY DRUG CLASS
119. 6.119 SOUTH AFRICA MARKET ANALYSIS BY DISEASE SEVERITY
120. 6.120 SOUTH AFRICA MARKET ANALYSIS BY PATIENT AGE GROUP
121. 6.121 SOUTH AFRICA MARKET ANALYSIS BY ETIOLOGY
122. 6.122 REST OF MEA MARKET ANALYSIS BY TYPE
123. 6.123 REST OF MEA MARKET ANALYSIS BY DRUG CLASS
124. 6.124 REST OF MEA MARKET ANALYSIS BY DISEASE SEVERITY
125. 6.125 REST OF MEA MARKET ANALYSIS BY PATIENT AGE GROUP
126. 6.126 REST OF MEA MARKET ANALYSIS BY ETIOLOGY
127. 6.127 KEY BUYING CRITERIA OF HEALTHCARE
128. 6.128 RESEARCH PROCESS OF MRFR
129. 6.129 DRO ANALYSIS OF HEALTHCARE
130. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE
131. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
132. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE
133. 6.133 HEALTHCARE, BY TYPE, 2024 (% SHARE)
134. 6.134 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion)
135. 6.135 HEALTHCARE, BY DRUG CLASS, 2024 (% SHARE)
136. 6.136 HEALTHCARE, BY DRUG CLASS, 2024 TO 2035 (USD Billion)
137. 6.137 HEALTHCARE, BY DISEASE SEVERITY, 2024 (% SHARE)
138. 6.138 HEALTHCARE, BY DISEASE SEVERITY, 2024 TO 2035 (USD Billion)
139. 6.139 HEALTHCARE, BY PATIENT AGE GROUP, 2024 (% SHARE)
140. 6.140 HEALTHCARE, BY PATIENT AGE GROUP, 2024 TO 2035 (USD Billion)
141. 6.141 HEALTHCARE, BY ETIOLOGY, 2024 (% SHARE)
142. 6.142 HEALTHCARE, BY ETIOLOGY, 2024 TO 2035 (USD Billion)
143. 6.143 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.2.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  4. 7.2.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  5. 7.2.5 BY ETIOLOGY, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.3.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.3.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  4. 7.3.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  5. 7.3.5 BY ETIOLOGY, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.4.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.4.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  4. 7.4.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  5. 7.4.5 BY ETIOLOGY, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.5.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.5.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  4. 7.5.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  5. 7.5.5 BY ETIOLOGY, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.6.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.6.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  4. 7.6.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  5. 7.6.5 BY ETIOLOGY, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.7.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.7.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  4. 7.7.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  5. 7.7.5 BY ETIOLOGY, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.8.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.8.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  4. 7.8.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  5. 7.8.5 BY ETIOLOGY, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.9.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.9.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  4. 7.9.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  5. 7.9.5 BY ETIOLOGY, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.10.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.10.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  4. 7.10.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  5. 7.10.5 BY ETIOLOGY, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.11.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.11.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  4. 7.11.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  5. 7.11.5 BY ETIOLOGY, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.12.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.12.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  4. 7.12.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  5. 7.12.5 BY ETIOLOGY, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.13.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.13.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  4. 7.13.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  5. 7.13.5 BY ETIOLOGY, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.14.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.14.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  4. 7.14.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  5. 7.14.5 BY ETIOLOGY, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.15.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.15.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  4. 7.15.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  5. 7.15.5 BY ETIOLOGY, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.16.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.16.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  4. 7.16.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  5. 7.16.5 BY ETIOLOGY, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.17.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.17.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  4. 7.17.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  5. 7.17.5 BY ETIOLOGY, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.18.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.18.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  4. 7.18.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  5. 7.18.5 BY ETIOLOGY, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.19.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.19.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  4. 7.19.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  5. 7.19.5 BY ETIOLOGY, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.20.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.20.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  4. 7.20.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  5. 7.20.5 BY ETIOLOGY, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.21.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.21.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  4. 7.21.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  5. 7.21.5 BY ETIOLOGY, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.22.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.22.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  4. 7.22.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  5. 7.22.5 BY ETIOLOGY, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.23.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.23.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  4. 7.23.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  5. 7.23.5 BY ETIOLOGY, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.24.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.24.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  4. 7.24.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  5. 7.24.5 BY ETIOLOGY, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.25.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.25.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  4. 7.25.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  5. 7.25.5 BY ETIOLOGY, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.26.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.26.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  4. 7.26.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  5. 7.26.5 BY ETIOLOGY, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.27.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.27.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  4. 7.27.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  5. 7.27.5 BY ETIOLOGY, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.28.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.28.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  4. 7.28.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  5. 7.28.5 BY ETIOLOGY, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.29.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.29.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  4. 7.29.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  5. 7.29.5 BY ETIOLOGY, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.30.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.30.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  4. 7.30.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
  5. 7.30.5 BY ETIOLOGY, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Hepatic Encephalopathy Treatment Market Segmentation

Hepatic Encephalopathy Treatment Market By Type (USD Billion, 2025-2035)

Drug Therapy
Liver Transplantation
Other Treatment Options

Hepatic Encephalopathy Treatment Market By Drug Class (USD Billion, 2025-2035)

Lactulose
Rifaximin
Antibiotics
Others

Hepatic Encephalopathy Treatment Market By Disease Severity (USD Billion, 2025-2035)

Mild Hepatic Encephalopathy
Moderate Hepatic Encephalopathy
Severe Hepatic Encephalopathy

Hepatic Encephalopathy Treatment Market By Patient Age Group (USD Billion, 2025-2035)

Pediatric
Adult

Hepatic Encephalopathy Treatment Market By Etiology (USD Billion, 2025-2035)

Cirrhosis
Hepatitis
Alcohol use disorder
Other

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”